

1 **Title:** High SARS-CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and
2 cellular responses

3
4 **Authors:** Sulaimon Akanmu,^{1*} Bobby Brooke Herrera,^{2,3,4,5*} Beth Chaplin,² Sade
5 Ogunsola,¹ Akin Osibogun,^{1,6} Fatima Onawoga,¹ Sarah John-Olabode,¹ Iorhen E.
6 Akase,¹ Augustina Nwosu,¹ Donald J Hamel,² Charlotte A Chang,² Phyllis J Kanki²

7
8 *Co-first author

9
10 **Affiliations:**

11 ¹Lagos University Teaching Hospital, College of Medicine, University of Lagos, Lagos,
12 Nigeria

13 ²Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public
14 Health, Boston, MA, USA

15 ³Department of Medicine, Division of Allergy, Immunology, and Infectious Diseases, and
16 Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School,
17 Rutgers University, New Brunswick, NJ, USA

18 ⁴Rutgers Global Health Institute, Rutgers University, New Brunswick, NJ, USA

19 ⁵Mir Biosciences, Inc., Boston, MA, USA

20 ⁶Lagos State COVID-19 Taskforce, Lagos State Ministry of Health, Lagos, Nigeria

21

22 Correspondence: PK, pkanki@hsph.harvard.edu

23

24 **Abstract:**

25 Background

26 Early evidence suggested that the impact of the COVID-19 pandemic was less
27 severe in Africa compared to other parts of the world. However, more recent studies
28 indicate higher SARS-CoV-2 infection and COVID-19 mortality rates on the continent than
29 previously documented. Research is needed to better understand SARS-CoV-2
30 seroprevalence and immunity in Africa.

31 Methods

32 Our collaboration with the Lagos State COVID-19 Taskforce, enabled secondary
33 analyses of immune responses in healthcare workers (HCWs) and Oxford/AstraZeneca
34 COVID-19 vaccine recipients from the general population across 5 local government
35 areas (LGAs) in Lagos State, Nigeria. Western blots were used to simultaneously detect
36 SARS-CoV-2 spike and nucleocapsid (N) antibodies and stimulation of peripheral blood
37 mononuclear cells with N followed by an IFN- γ ELISA was used to examine T cell
38 responses.

39 Findings

40 Antibody data demonstrated high SARS-CoV-2 seroprevalence of 71.6% (96/134)
41 in HCWs and 54.8% (63/115) in the general population. Antibodies directed to only
42 SARS-CoV-2 N, suggesting pre-existing coronavirus immunity, were seen in 10.4%
43 (14/134) of HCWs and 20.0% (23/115) of the general population. T cell data showed that
44 IFN- γ responses against SARS-CoV-2 N were robust in detecting exposure to the virus,
45 demonstrating 87.5% sensitivity and 92.3% specificity.

46 Interpretation

47 These results have important implications for understanding the paradoxical high
48 SARS-CoV-2 infection with low mortality rate in Africa as compared to other parts of the
49 world, as well as for the development of T cell-based diagnostics and vaccines.

50

51 Funding

52 Harvard University, Motsepe Presidential Research Accelerator Fund for Africa

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70 **Introduction:**

71

72 Early projections of SARS-CoV-2 spread in Africa fueled fears that the healthcare
73 infrastructure on the continent would be ill prepared to cope with the anticipated COVID-
74 19 hospitalizations and deaths (1). However, as of October 2022, 12.1 million COVID-19
75 cases and 256,000 deaths have been reported in Africa, representing ~2% and ~4% of
76 global statistics, respectively. Early studies indicated a less severe epidemiological
77 picture of COVID-19 in Africa, with a higher proportion of cases resulting in asymptomatic
78 infections and lower mortality compared to other parts of the world (2). Several factors
79 may help explain these phenomena including the younger age demographics with
80 stronger immune status, climate and environmental factors, and weak health systems for
81 reporting (3-5).

82 In Africa, SARS-CoV-2 prevalence studies conducted in blood donors, healthcare
83 workers (HCWs), pregnant women, and others have described varying rates during
84 different time periods, ranging from 0.4% in Cape Verde (June-July 2020) to more than
85 49% in Kenya (August 2020-October 2021) and 79% across 12 states in Nigeria (June-
86 August 2021) (6-8). In most cases, the reported prevalence of antibodies against SARS-
87 CoV-2 was several orders of magnitude higher than would be expected from PCR
88 confirmed cases. However, more recent evidence indicates an underestimation of
89 COVID-19's impact in Africa. In Zambia, postmortem surveillance conducted between
90 June 15 and October 1, 2020, detected SARS-CoV-2 RNA in ~20% of subjects sampled
91 within 48 hours of death, and only 2 of the 70 had been diagnosed with SARS-CoV-2
92 prior to death (9). A follow-up study showed that during peak transmission periods,

93 approximately 90% of all deceased individuals tested positive for COVID-19 (10). While
94 these studies demonstrate under-reporting of SARS-CoV-2 infection, there remains a lack
95 of evidence for major increases in mortality, at least suggestive of lower pathogenic
96 impact.

97 The humoral response to SARS-CoV-2 has been the primary focus of most studies
98 conducted in Africa. A study of pre-pandemic samples in Gabon and Senegal,
99 demonstrated significant pre-existing immunity based on antibodies directed to the
100 SARS-CoV-2 spike (S) and nucleocapsid (N) proteins, in contrast to samples from
101 Canada, Brazil and Denmark (11). However, Gabonese sera with or without antibodies
102 to SARS-CoV-2 N were unable to neutralize the virus in vitro or in mouse infection studies.
103 These data, along with other published studies confirm pre-existing humoral responses
104 to SARS-CoV-2 that may be qualitatively and quantitatively distinct in Africa.

105 The study of T cell responses has also been used in research and clinical settings
106 during the COVID-19 pandemic to provide further insights into the immune response to
107 infection and/or vaccination. In contrast to humoral responses, T cell responses to human
108 coronaviruses, including SARS-CoV-1 and SARS-CoV-2, may be long-lasting even many
109 years after infection (12, 13). SARS-CoV-2-specific T cells were maintained at 6-9 months
110 following primary infection, indicating that T cell immunity may persist beyond antibody
111 responses (12). Preclinical development of SARS-CoV-2 vaccines have demonstrated T
112 cell responses accompanying antibody responses and clinical studies are now
113 demonstrating similar timelines following vaccination (14). These findings, together with
114 studies that have demonstrated a role for T cells in viral clearance, suggest that cell-
115 mediated immune responses may be an important component of protection against

116 SARS-CoV-2 (15). Here we report the results of antibody and T cell analyses using
117 Nigerian samples from HCWs and a group of vaccine recipients from the general
118 population prospectively followed post-vaccination. To our knowledge, this is the first
119 study to examine both the antibody and T cell response to SARS-CoV-2 in West Africans.

120

121 **Methods:**

122

123 Study Population and Ethics Statement

124

125 Our original study in early 2021 proposed to only recruit HCWs, a population with
126 high-risk occupational exposure to COVID-19. However, the roll-out of COVID-19
127 vaccines in Nigeria at the end of March 2021 enabled study of vaccine recipients from
128 communities also from Lagos state. The Oxford AstraZeneca vaccine, with its low cost
129 and simple refrigeration requirements enabled equitable access for low- and middle-
130 income countries and was the first non-profit vaccine to report efficacy. The
131 recommended initial course is two doses, administered intramuscularly with an interval of
132 8–12 weeks between doses.

133 The HCW cohort was recruited from the Lagos University Teaching Hospital
134 (LUTH). Study participation included a brief clinical examination, questionnaire and
135 venous blood sample. HCWs included some with documented prior COVID-19 infection
136 by PCR. HCW samples were collected between March and October 2021.

137 The Lagos State Vaccine study population included individuals from the general
138 population from Agbowo, Amuwo, Ikorodu, Iwaya, and Oshodi, Lagos State, Nigeria, all

139 of whom, at the time of enrollment, had no documented history of SARS-CoV-2 infection
140 and were administered the first dose of the Oxford/AstraZeneca COVID-19 vaccine
141 between March to June 2021. A brief questionnaire on demographics and exposure was
142 administered at baseline, and venous blood samples were collected at baseline
143 (immediately before vaccination), 7-, 14-, and 84-days after vaccination for immune
144 response testing.

145 All individuals from each of the 2 cohorts provided written informed consent for the
146 collection of samples and data. The HCW study received ethical clearance from the
147 Harvard T.H. Chan School of Public Health Institutional Review Board (IRB, Protocol #:
148 IRB-21-0329) and the LUTH Health Research Ethics Committee (HREC, Protocol #:
149 ADM/DCST/HREC/APP/4192). The original Lagos State COVID-19 Vaccine study was
150 reviewed and approved by the LUTH HREC (Protocol #: ADM/DCST/HREC/APP/4207),
151 and the secondary analysis of these samples was determined not human subjects
152 research by the Harvard IRB (Protocol #: IRB21-1350).

153

154 Viral Lysate

155

156 Briefly, Vero cells infected with SARS-CoV-2 (Isolate USA-WA1/2020, BEI
157 Resources NR-52281) were lysed when cytopathic effect were observed in 20% of cells
158 with lysis buffer containing protease inhibitors, followed by centrifugation at 170,000 x g
159 at 4°C for 90 minutes to obtain cell lysates. Aliquots of cell lysates were purified by
160 sucrose gradient.

161

162 Western Blot

163

164 Aliquots of cell lysates were added to nonreducing buffer (final concentrations of
165 2% SDS, 0.5 M Tris pH 6.8, 20% glycerol, 0.001% bromophenol blue) and subjected to
166 12% PAGE and Western blot analysis using patient serum (1:250) as primary antibody
167 and anti-human IgG horseradish peroxidase (HRP) (1:2,000; ThermoFisher Scientific,
168 Waltham, MA) as secondary antibody. Visualization was performed using Metal
169 Enhanced DAB Substrate Kit (ThermoFisher Scientific, Waltham, MA) per the
170 manufacturer's instructions.

171

172 Image analysis

173

174 Western blots were analyzed using image processing software, ImageJ (NIH), to
175 machine-read and quantify SARS-CoV-2 S antibody signals. The average pixel intensity
176 was quantified at the Western blot SARS-CoV-2 S band, background areas, and a control
177 band. The background-adjusted SARS-CoV-2 S band signal was then normalized to the
178 background-subtracted control band and expressed as % of control.

179

180 T cell stimulation

181

182 From each individual, 3 ml whole blood was collected in a vacutainer tube treated
183 with lithium or sodium heparin (BD, Franklin Lakes, NJ), and tubes were inverted 10 times
184 to ensure that the blood mixed thoroughly with the anticoagulant. 1 ml whole blood was

185 then pipetted into three MASI Stimulator Tubes (Mir Biosciences, Boston, MA) either
186 coated with SARS-CoV-2 N, positive control (phytohemagglutinin), or negative control
187 (PBS). All tubes were then inverted 25 times to ensure that the whole blood mixed
188 thoroughly along the inner walls of the MASI Stimulator Tubes. The MASI Stimulator
189 Tubes were incubated in a humidified incubator at 37°C with 5% CO₂ for 18-22 hours.
190 After the incubation step, the MASI Stimulator Tubes were centrifuged at 2,500 x g for 5
191 minutes and the supernatant was aliquoted into 1 ml cryotubes and immediately
192 processed by the IFN-γ ELISA.

193

194 IFN-γ ELISA

195

196 Supernatants (100 μl) collected from the MASI Stimulator Tubes were screened
197 for the presence of human IFN-γ by the MASI-COVID enzyme-linked immunosorbent
198 assay (ELISA) (Mir Biosciences, Boston, MA), according to the manufacturer's
199 instructions. The presence of IFN-γ was captured using a microplate reader (optical
200 density 450 nm). Assay performances were monitored using internal controls and cutoffs
201 were determined as specified by the manufacturer for the kit.

202

203 Statistics

204 For both the HCW and general population vaccine recipient cohorts, we calculated
205 baseline SARS-CoV-2 S and N antibody seroprevalence determined by Western blot as
206 percentage of total. Using these seroprevalence categories, we evaluated T cell
207 responses after stimulation with SARS-CoV-2 N by plotting IFN-γ ELISA signal in a subset

208 of HCW baseline samples and 7-day post-vaccination general population samples.
209 Additionally, for the vaccine recipient cohort, we used the Western blot and image
210 analysis to evaluate boosting of SARS-CoV-2 S antibodies in sequential samples post-
211 vaccination by calculating mean S signal and change over time. The mean S antibody
212 signal between groups was compared by T-test. Finally, we calculated sensitivity and
213 specificity of IFN- γ responses against SARS-CoV-2 N. All statistics and plots were
214 generated using Prism (version 9.0.0).

215

216 Role of the funding source

217

218 Authors declare that the funder did not have any role in the study design; in the
219 collection, analysis, and interpretation of data; in the writing of the report; and in the
220 decision to submit the paper for publication.

221

222 **Results:**

223

224 Our study included a cohort of 134 HCWs working at LUTH. Forty HCWs
225 previously tested positive for COVID-19 by RT-PCR and 94 did not have history of
226 documented SARS-CoV-2 infection. (Table 1). Our study also included a second cohort
227 of 126 individuals from the general population across 5 local government areas of Lagos
228 State: 25 from Agbowa, 26 from Amuwo, 25 from Ikorodu, 25 from Iwaya, and 25 from
229 Oshodi (Table 1). At the time of enrollment, referred to throughout as baseline, a blood
230 sample was collected from each individual, immediately prior to administration of the first

231 dose of the Oxford/AstraZeneca COVID-19 vaccine. For these individuals, baseline and
232 follow-up samples were collected between March and August 2021.

233 We analyzed the SARS-CoV-2 seroprevalence based on antibodies directed
234 against SARS-CoV-2 S+N or S-only. The overall seroprevalence of SARS-CoV-2 in
235 HCWs was 71.6% (96/134) (Table 1). Of HCWs with previous RT-PCR confirmation of
236 COVID-19, 100% (40/40) had SARS-CoV-2 S+N or S-only antibodies (Table 1). Of HCWs
237 without any prior history, 58.5% (55/94) had SARS-CoV-2 S+N antibodies, whereas 1.1%
238 (1/94) had S-only antibodies (Table 1). We then examined the T cell response against
239 SARS-CoV-2 N. In HCWs with SARS-CoV-2 S+N antibodies, 82.6% (19/23) had a T cell
240 response against N (Fig. 1A).

241 We next examined HCWs with antibodies directed against SARS-CoV-2 N-only,
242 suggestive of pre-existing coronavirus immunity. There was reactivity to N-only in 10.4%
243 (14/134) of HCWs, all with no history of PCR-confirmed SARS-CoV-2 infection (Table 1).
244 Of those we tested for T cell responses, 100% (1/1) had a T cell response against SARS-
245 CoV-2 N (Fig. 1B). Additionally, 17.9% (24/134) of HCWs were seronegative to SARS-
246 CoV-2. Of those we tested, 75% (6/8) did not have a T cell response against SARS-CoV-
247 2 N (Table 1, Fig. 1C).

248 We similarly analyzed the SARS-CoV-2 antibody profiles in the general population
249 vaccine recipients. At baseline, the overall SARS-CoV-2 seroprevalence was 54.8%
250 (63/115), with reactivity to SARS-CoV-2 N-only in 20% (23/115), suggestive of pre-
251 existing coronavirus immunity (Table 1). 25.2% of the general population vaccine
252 recipients were seronegative (29/115). Across the five local government areas, SARS-
253 CoV-2 seroprevalence ranged from 34.8% in Amuwo to 66.7% in Ikorodu. The reactivity

254 to SARS CoV-2 N-only was more consistent across the local government areas, ranging
255 from 16.7% in Ikorodu to 22.7% in Oshodi (Table 1).

256 Given that the Oxford/AstraZeneca COVID-19 vaccine is designed to generate
257 immunity against the SARS-CoV-2 S, we next examined the evolution of SARS-CoV-2 S
258 antibodies post-vaccination. Most individuals, regardless of their SARS-CoV-2 antibody
259 status at baseline, had detectable S antibodies post-vaccination (Fig. 2A-E). However,
260 the potency of the SARS-CoV-2 S antibody response differed between baseline antibody
261 profile groups. The S antibody response was significantly stronger in individuals with
262 baseline SARS-CoV-2 S+N antibodies compared to those with N-only antibodies or
263 seronegatives at 7- ($p < 0.0001$ or $p < 0.0003$, respectively) and 14-days ($p < 0.002$ or p
264 < 0.02 , respectively) post-vaccination (Fig. 2F). For the SARS-CoV-2 S+N baseline
265 group, the S antibody response remained significantly stronger only compared to the
266 seronegative group at 84-days post-vaccination ($p < 0.03$) (Fig. 2F). The SARS-CoV-2 S-
267 only baseline group had a significantly stronger S antibody response compared to the N-
268 only baseline group only at 7-days post-vaccination ($p < 0.005$) (Fig. 2F). The SARS-
269 CoV-2 N-only baseline group had a significantly stronger S antibody response compared
270 to the seronegative baseline group only at 84-days post-vaccination ($p < 0.004$) (Fig. 2F).
271 Also, 6 of 115 individuals (5.2%), all of whom were seronegative at baseline, failed to
272 develop SARS-CoV-2 S antibodies 4 weeks after the second vaccine dose (Fig. 2D-E).

273 Since some individuals already had SARS-CoV-2 S antibodies at baseline,
274 suggesting prior SARS CoV-2 infection, we also examined the levels of S boosting post-
275 vaccination. In individuals with SARS-CoV-2 S+N antibodies at baseline, 74.4% of S
276 boosting occurred within 7-days post vaccination, followed by 24.5% and 1.2% within 14-

277 and 84-days post-vaccination, respectively (Fig. 3). For individuals with S-only antibodies
278 or were seronegative at baseline, ~36.6% of S boosting occurred within 7-days post-
279 vaccination, followed by 56.4% and ~7% within 14- and 84-days post-vaccination,
280 respectively (Fig. 3). S boosting in individuals with SARS-CoV-2 N-only antibodies at
281 baseline differed compared to other groups, with relatively consistent levels between time
282 periods. For these individuals, 22.9%, 39.9%, and 37.2% of S boosting occurred within
283 7-, 14-, and 84-days post-vaccination, respectively (Fig. 3).

284 We then examined the T cell response against SARS-CoV-2 N in individuals in the
285 general population 7-days post-vaccination. In individuals with SARS-CoV-2 S+N
286 antibodies, 55.9% (33/59) had a T cell response against SARS-CoV-2 N (Fig. 4A). In
287 individuals with N-only antibodies 100% (2/2) had T cell responses against SARS-CoV-2
288 N, respectively (Fig. 4B). In individuals who were seronegative, 100% (18/18) did not have
289 T cell responses against SARS-CoV-2 N (Fig. 4C).

290 Finally, we calculated the sensitivity and specificity to determine the efficacy of
291 using T cell IFN- γ against SARS-CoV-2 N as a diagnostic biomarker for exposure. The
292 positive control group consisted of 16 HCWs with previous RT-PCR confirmation of
293 COVID-19 and the negative control group consisted of 26 HCWs and individuals in the
294 general population who were seronegative. The resulting sensitivity was 87.5% and the
295 specificity was 92.3% (Table 2).

296

297 **Discussion:**

298

299 In Africa, the immunological response to SARS-CoV-2 and non-SARS
300 coronaviruses represents a critical research gap that may shed light on the paradoxical
301 high SARS-CoV-2 infection with low mortality rate as compared to other parts of the world.
302 The goal of the present study was to profile the antibody and T cell responses in natural
303 SARS-CoV-2 infection and COVID-19 vaccination in two Nigerian cohorts. There are four
304 important findings from our study. First, antibodies directed against SARS-CoV-2 S+N,
305 suggestive of previous exposure the virus, were observed in a majority of individuals prior
306 to vaccination. These results agree with other SARS-CoV-2 seroprevalence studies,
307 suggesting a very high infection rate by 2021. Second, having antibodies to SARS CoV-
308 2 N-only is suggestive of pre-existing coronavirus immunity, as represented by HCWs
309 and the general population with N-only antibodies prior to vaccination. Third, SARS-CoV-
310 2 S antibody boosting occurs more rapidly in individuals with prior SARS-CoV-2 infection.
311 Finally, T cell IFN- γ against SARS-CoV-2 N is a robust method to detect exposure to the
312 virus as demonstrated by the high detection rate among the HCWs with prior PCR-
313 confirmed COVID-19.

314 Studies have shown that the antibody response to natural infection by SARS-CoV-
315 2 is highly variable (16). In some cases, individuals never produce a detectable antibody
316 response, or low antibody titers have been observed in individuals with mild or
317 asymptomatic infections (16, 17). The vast majority of antibody studies have utilized
318 ELISA assays to recombinant SARS CoV-2 antigens. Multiple studies now indicate
319 reduced specificity of these assays when analyzing samples originating from sub-
320 Saharan Africa (11, 18). Of note, our study employed virion based immunoblot which

321 enabled simultaneous visualization of antibody responses to multiple SARS-CoV-2
322 antigens with multiple positive and negative controls to ensure specificity.

323 Our antibody data showed a high SARS-CoV-2 seroprevalence in Nigeria with
324 strong antibody reactivity. A majority of individuals, including 71.6% of HCWs and 54.8%
325 of the general population vaccine recipients, had antibodies directed against SARS-CoV-
326 2 S+N (Table 1). These data are in comparison to studies conducted in Nigeria between
327 June and December 2020 showing lower seroprevalence rates ranging between 17-25%
328 (19, 20).

329 While COVID-19 vaccines have also been shown to induce robust antibody
330 responses, there is strong evidence that these responses decline in the months following
331 the second or boosting doses (21, 22). Our data demonstrate that a majority of general
332 population vaccine recipients, regardless of baseline antibody status, developed SARS-
333 CoV-2 S antibodies post-vaccination (Fig. 2). However, six individuals (5.2% across
334 vaccine population) failed to develop an antibody response even after two vaccine rounds
335 (Fig. 2D-E). Moreover, previous SARS-CoV-2 immunity appears to impact the level of S
336 antibody boosting. Vaccination with the Oxford/AstraZeneca COVID-19 vaccine boosted
337 74% of S antibodies within 7 days in individuals who already had SARS-CoV-2 S+N
338 antibodies at baseline (Fig. 3). In contrast, only 39%, 23%, or 34% of S boosting occurred
339 within 7 days in individuals who demonstrated S-only or N-only antibodies or were
340 seronegative at baseline, respectively (Fig. 3). Importantly, analysis was not performed
341 on samples beyond 84-days post-vaccination; therefore, we are unable to postulate on
342 antibody waning. However, several studies have demonstrated substantial antibody
343 waning after vaccination with the Oxford/AstraZeneca COVID-19 vaccine (23).

344 During infection with SARS-CoV-2, S and N proteins are major targets of both
345 antibodies and T cells (24). While SARS-CoV-2 S protein is more genetically diverse
346 among coronavirus infected humans and animals, the N protein is highly conserved (25).
347 Our antibody data suggests pre-existing coronavirus immunity with 10.4% (14/134) of
348 HCWs and 20% (23/115) of individuals in the general population who only had SARS-
349 CoV-2 N antibodies prior to vaccination. These results recapitulate other studies
350 highlighting a similar phenomenon (11, 18, 26). SARS-CoV-2 N seropositivity could
351 suggest undocumented infections with other as yet unrecognized coronaviruses,
352 including animal coronaviruses. There is 93-100% homology between SARS-CoV-2 and
353 several bat and pangolin N proteins at the amino acid level, and both alpha and
354 betacoronaviruses have been isolated from animals in Central and West Africa (11, 27,
355 28). The dynamics of antibody waning post natural infection is not well studied. It is
356 possible that waning of S antibodies may result in the SARS-CoV-2 N antibody only
357 profile. Prospective serologic studies are needed in these populations to further elucidate
358 this finding.

359 We also report, for the first time, T cell responses against SARS-CoV-2 N in West
360 Africans. The T cell assay used in this study does not require peripheral blood
361 mononuclear cell (PBMC) isolation, offering ease-of-use and a more time-sensitive
362 procedure from sampling to result. Instead, an individual's whole blood is collected in
363 lithium heparin tubes, followed by T cell stimulation in the kit's specialized tubes coated
364 with SARS-CoV-2 N protein or positive/negative controls. After stimulation, supernatants
365 are processed via a one-step ELISA to measure IFN- γ secreted by T cells that responded
366 to the SARS-CoV-2 N protein.

367 Evidence suggests that most individuals infected with SARS-CoV-2 generate IFN-
368 γ -producing T cells that can be detected in peripheral blood as early as 2-4 days from the
369 onset of symptoms or between 7-14 days after vaccination (29, 30). Our results
370 demonstrate a high sensitivity and specificity in detecting exposure to SARS-CoV-2
371 based on whole blood IFN- γ . In HCWs with previous RT-PCR confirmation of COVID-19,
372 the sensitivity of T cell IFN- γ against SARS-CoV-2 N was 87.5%. The specificity of the
373 assay in individuals who were seronegative was 92.3% (Table 2). In individuals from the
374 general population who were seronegative, none had detectable T cell IFN- γ responses.
375 However, two HCWs who were seronegative had a positive T cell response. These may
376 have been false positives or the T cell response to SARS-CoV-2 N was skewed by pre-
377 existing immunity to other pathogens including globally endemic human non-SARS
378 coronaviruses (25).

379 This study has limitations. Our study populations of HCWs and the general
380 population of vaccine recipients were relatively small. Second, while our results are
381 suggestive of pre-existing coronavirus immunity, it was not within the scope of the study
382 to confirm the specific coronavirus responsible for the response. Studies will be required
383 to determine whether pre-existing coronavirus immunity may alter susceptibility to SARS-
384 CoV-2 infection and/or COVID-19 severity. Third, the focus of the T cell response was on
385 SARS-CoV-2 N. While we observed robust responses to N, there are other proteins that
386 have been shown to be targeted by T cells, which may correlate with disease severity.
387 Finally, due to the limited amount of blood collected for each patient, we were unable to
388 define the CD4- and CD8-specific T cell responses.

389 In conclusion, our study demonstrates high SARS-CoV-2 seroprevalence as well
390 as possible preexisting coronavirus immunity in the Nigerian population in 2021, and also
391 provides new data on T cell responses as well as antibody boosting after vaccination
392 based on prior infection/exposure. Our findings highlight the need for further
393 investigations to better understand the immune mechanisms and consequences related
394 to pre-existing coronavirus immunity in West Africa. Pre-existing B cell and/or T cell
395 memory may have important implications for natural infection and disease outcomes.
396 Identification of conserved antibody and/or T cell epitopes may hold promise for improved
397 vaccines protecting against current and future coronaviruses.

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412 **References:**

413

414 1. Gilbert M, Pullano G, Pinotti F, Valdano E, Poletto C, Boelle PY, et al.
415 Preparedness and vulnerability of African countries against importations of COVID-19: a
416 modelling study. *Lancet*. 2020;395(10227):871-7.

417 2. Tessema SK, Nkengasong JN. Understanding COVID-19 in Africa. *Nat Rev*
418 *Immunol*. 2021;21(8):469-70.

419 3. Sajadi MM, Habibzadeh P, Vintzileos A, Shokouhi S, Miralles-Wilhelm F, Amoroso
420 A. Temperature, Humidity, and Latitude Analysis to Estimate Potential Spread and
421 Seasonality of Coronavirus Disease 2019 (COVID-19). *JAMA Netw Open*.
422 2020;3(6):e2011834.

423 4. Gaye B, Khoury S, Cene CW, Kingue S, N'Guetta R, Lassale C, et al. Socio-
424 demographic and epidemiological consideration of Africa's COVID-19 response: what is
425 the possible pandemic course? *Nat Med*. 2020;26(7):996-9.

426 5. Wamai RG, Hirsch JL, Van Damme W, Alnwick D, Bailey RC, Hodgins S, et al.
427 What Could Explain the Lower COVID-19 Burden in Africa despite Considerable
428 Circulation of the SARS-CoV-2 Virus? *Int J Environ Res Public Health*. 2021;18(16).

429 6. Gomez LF, Mendes C, Silva JS, Semedo FH, Barreto JN, Monteiro Rodrigues J,
430 et al. Sero-epidemiological survey and profile of SARS-CoV-2 infection in Cape Verde.
431 Available at SSRN 3762489. 2021.

432 7. Lucinde R, Mugo D, Bottomley C, Aziza R, Gitonga J, Karanja H, et al. Sero-
433 surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral
434 hospitals. *MedRxiv*. 2021.

- 435 8. Kolawole OM, Tomori O, Agbonlahor D, Ekanem E, Bakare R, Abdulsalam N, et
436 al. SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in
437 Nigeria. *JAMA Netw Open*. 2022;5(10):e2236053.
- 438 9. Mwananyanda L, Gill CJ, MacLeod W, Kwenda G, Pieciak R, Mupila Z, et al.
439 Covid-19 deaths in Africa: prospective systematic postmortem surveillance study. *BMJ*.
440 2021;372:n334.
- 441 10. Gill CJ, Mwananyanda L, MacLeod W, Kwenda G, Pieciak R, Etter LE, et al.
442 Sustained high prevalence of COVID-19 deaths from a systematic post-mortem study in
443 Lusaka, Zambia: one year later. *medRxiv*. 2022.
- 444 11. Pedersen J, Koumakpayi IH, Babuadze G, Baz M, Ndiaye O, Faye O, et al. Cross-
445 reactive immunity against SARS-CoV-2 N protein in Central and West Africa precedes
446 the COVID-19 pandemic. *Sci Rep*. 2022;12(1):12962.
- 447 12. Zuo J, Dowell AC, Pearce H, Verma K, Long HM, Begum J, et al. Robust SARS-
448 CoV-2-specific T cell immunity is maintained at 6 months following primary infection. *Nat*
449 *Immunol*. 2021;22(5):620-6.
- 450 13. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-
451 CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.
452 *Nature*. 2020;584(7821):457-62.
- 453 14. Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2
454 vaccination induces immunological T cell memory able to cross-recognize variants from
455 Alpha to Omicron. *Cell*. 2022;185(5):847-59 e11.

- 456 15. Tan AT, Linster M, Tan CW, Le Bert N, Chia WN, Kunasegaran K, et al. Early
457 induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance
458 and mild disease in COVID-19 patients. *Cell Rep.* 2021;34(6):108728.
- 459 16. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson
460 E, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. *N Engl J Med.*
461 2020;383(18):1724-34.
- 462 17. Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et
463 al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus
464 severe COVID-19. *J Allergy Clin Immunol.* 2021;147(2):545-57 e9.
- 465 18. Emmerich P, Murawski C, Ehmen C, von Possel R, Pekarek N, Oestereich L, et
466 al. Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum
467 samples of African origin. *Trop Med Int Health.* 2021;26(6):621-31.
- 468 19. Majiya H, Aliyu-Paiko M, Balogu VT, Musa DA, Salihu IM, Kawu AA, et al.
469 Seroprevalence of SARS-CoV-2 in Niger State: A Pilot Cross Sectional Study. *MedRxiv.*
470 2021:2020.08.04.20168112.
- 471 20. Okpala OV, Dim CC, Ugwu CI, Onyemaechi S, Uchebo O, Chukwulobelu U, et al.
472 Population seroprevalence of SARS-CoV-2 antibodies in Anambra State, South-East,
473 Nigeria. *Int J Infect Dis.* 2021;110:171-8.
- 474 21. Naaber P, Tserel L, Kangro K, Sepp E, Jurjenson V, Adamson A, et al. Dynamics
475 of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective
476 study. *Lancet Reg Health Eur.* 2021;10:100208.

- 477 22. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning Immune
478 Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. *N Engl J Med.*
479 2021;385(24):e84.
- 480 23. Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy E, et al.
481 Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. *Lancet.*
482 2021;398(10298):385-7.
- 483 24. Jiang HW, Li Y, Zhang HN, Wang W, Yang X, Qi H, et al. SARS-CoV-2 proteome
484 microarray for global profiling of COVID-19 specific IgG and IgM responses. *Nat*
485 *Commun.* 2020;11(1):3581.
- 486 25. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, Genetic
487 Recombination, and Pathogenesis of Coronaviruses. *Trends Microbiol.* 2016;24(6):490-
488 502.
- 489 26. Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, et al.
490 Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not
491 associated with protection. *Cell.* 2021;184(7):1858-64 e10.
- 492 27. Maganga GD, Pinto A, Mombo IM, Madjitobaye M, Mbeang Beyeme AM,
493 Boundenga L, et al. Genetic diversity and ecology of coronaviruses hosted by cave-
494 dwelling bats in Gabon. *Sci Rep.* 2020;10(1):7314.
- 495 28. Lacroix A, Vidal N, Keita AK, Thaurignac G, Esteban A, De Nys H, et al. Wide
496 Diversity of Coronaviruses in Frugivorous and Insectivorous Bat Species: A Pilot Study in
497 Guinea, West Africa. *Viruses.* 2020;12(8).
- 498 29. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell.*
499 2021;184(4):861-80.

500 30. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et
501 al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19
502 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021;27(2):270-8.

503

504 **Acknowledgments:**

505

506 We thank the many healthcare workers at Lagos University Teaching Hospital
507 that participated in this study. We also acknowledge the collaboration with the Lagos
508 State COVID-19 Taskforce in the evaluation of COVID-19 vaccine immunity. This study
509 was funded by Harvard University's Motsepe Presidential Research Accelerator Fund
510 for Africa.

511

512 **Author Contributions:**

513

514 Conceptualization: SA, BBH, PJK. Methodology: SA, BBH, BC, SO, AO, FO, SJO, IEA,
515 AN, DJH, CAC, PJK. Validation: SA, BBH, BC, SO, AO, FO, SJO, IEA, AN, DJH, CAC,
516 PJK. Formal Analysis: SA, BBH, BC, AO, DJH, CAC, PJK. Data Curation: SA, BBH, BC,
517 SO, AO, FO, SJO, IEA, AN, DJH, CAC, PJK. Writing – Original Draft Preparation: BBH.
518 Writing – Review & Editing: SA, BBH, BC, SO, AO, FO, SJO, IEA, AN, DJH, CAC, PJK.
519 Visualization: BBH, BC, CAC, PJK. Supervision: SA, AO, PJK. Funding Acquisition: PJK.

520

521 **Data Availability Statement:**

522

523 All data produced in the present study are available upon reasonable request to
524 the corresponding author.

525

526 **Declaration of Interests:**

527 BBH is a co-founder of Mir Biosciences, Inc., a company that develops T cell-
528 based diagnostics/vaccines for infections, cancer, and autoimmunity.

529

530

531

532

533

534

535

536

537

538

539

540

541


542

543

544

545

546
547
548
549




550
551

552 **Fig. 1. T cell responses to SARS-CoV-2 nucleocapsid (N) in healthcare workers**
553 **(HCWs).** Whole blood samples were stimulated with SARS-CoV-2 N, then supernatants
554 were processed via an IFN- γ enzyme-linked immunosorbent assay for healthcare workers
555 who had antibodies to A) SARS-CoV-2 S+N, B) N-only, or C) were seronegative.
556 Responses are expressed as an arbitrary unit (IFN- γ signal) based on an OD₄₀₅
557 measurement. Dashed line, assay cutoff.

558
559
560
561
562

563

564



565

566

567 **Fig. 2. Evolution and boosting of SARS-CoV-2 spike (S) in individuals in the general**

568 **population post-vaccination.** Sera sequentially collected from vaccine recipients in the

569 general population were subjected to Western blot analysis. The post-vaccination

570 evolution of SARS-CoV-2 S antibodies for each individual with baseline antibodies to A)

571 SARS-CoV-2 S+N, B) S-only, C) N-only, or D) who were seronegative (red lines represent

572 individuals who never developed S antibodies even after two vaccine rounds) determined

573 by image analysis where the S antibody signal was calculated and plotted as a % of

574 control. The x-axis corresponds to number of days post-vaccination. The y-axis

575 corresponds to background subtracted SARS-CoV-2 S signal normalized to the control

576 line for each Western blot. Dashed line, cutoff. E) The evolution of SARS-CoV-2 S

577 antibodies was determined by image analysis where the S antibody signals were

578 calculated and plotted as the mean S signal by time period for each baseline antibody
579 profile group. Dashed line, cutoff. F) Representative image of Western blots for groups of
580 individuals.

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597


598

599

600

601

602



603

604 **Fig. 3. Boosting of SARS-CoV-2 spike (S) in individuals in the general population**

605 **post-vaccination.** Sera sequentially collected from individuals in the general population

606 were subjected to Western blot analysis. The level of antibody boosting was determined

607 by subtracting the mean SARS-CoV-2 S antibody signal between baseline and 7-days

608 post-vaccination, 7- and 14-days post-vaccination, and 14- and 84-days post-vaccination.

609 The S signals from each time period were then summed and plotted as a % of total in a

610 stacked format.

611

612

613

614


615

616

617

618

619



620

621

622 **Fig. 4. T cell responses to SARS-CoV-2 nucleocapsid (N) 7-days post-vaccination**

623 **in individuals in the general population.** Whole blood samples were stimulated with

624 SARS-CoV-2 N, then supernatants were processed via an IFN- γ enzyme-linked

625 immunosorbent assay for individuals in the general population who had antibodies to A)

626 SARS-CoV-2 S+N, B) N-only, or C) were seronegative. Responses are expressed as an

627 arbitrary unit (IFN- γ signal) based on an OD₄₀₅ measurement. Dashed line, assay cutoff.

628

629

630

631

632

633

634

635

636 **Tables:**

637

638 Table 1. SARS-CoV-2 antibody seroprevalence among healthcare workers and the
639 general population.

640

Cohort	Number	Antibody Seroprevalence at Baseline			
		SARS-CoV-2: S+N Number Positive (%)	SARS-CoV-2: S-only Number Positive (%)	SARS-CoV-2: N-only Number Positive (%)	Seronegative Number Positive (%)
Healthcare Workers					
COVID-19 convalescent	40	38 (95.0)	2 (5.0)	-	-
No history of COVID-19	94	55 (58.5)	1 (1.1)	14 (14.9)	24 (25.5)
Overall	134	93 (69.4)	3 (2.2)	14 (10.4)	24 (17.9)
General Population – Vaccine Recipients					
Agbowa	24	15 (62.5)	1 (4.2)	5 (20.8)	3 (12.5)
Amuwo	23	8 (34.8)	1 (4.4)	5 (21.7)	9 (39.1)
Ikorodu	24	16 (66.7)	-	4 (16.7)	4 (16.7)
Iwaya	22	9 (40.9)	1 (4.6)	4 (18.2)	8 (36.4)
Oshodi	22	12 (54.6)	-	5 (22.7)	5 (22.7)
All sites	115	60 (52.2)	3 (2.6)	23 (20.0)	29 (25.2)

641

642

643

644 Table 2. Performance of T cell IFN- γ against SARS-CoV-2 N in control groups.

645

Statistic	Value	95% Confidence Intervals
Sensitivity	87.50% (14/16)	61.65% to 98.45%
Specificity	92.31% (24/26)	74.87% to 99.05%
Positive Predictive Value	87.50%	64.60% to 96.41%
Negative Predictive Value	93.10%	76.56% to 97.78%

646